News
NIH inventors have developed an image-based machine learning system that is able to validate functional cell phenotypes. The system may be trained to automatically recognize image features that correlate with a desired cell-type or properties for research, diagnostic, and therapeutic purposes. This
NIH inventors have developed the first pharmacologic option for developmental stuttering, which is currently only managed by speech therapy, but addresses a $3 billion underserved global market. This technology uses small-molecule iron chelators – drugs that bind and remove excess iron – for the
Broad access to the fruits of NIH’s investments—whether in the form of data, results, or products—drives innovation. To advance this aim, NIH is launching a new policy to improve access to medical products developed from NIH-owned inventions. This policy emphasizes the importance of proactive
Meet with NIH Technology Transfer experts at the BioHealth Capital Region Forum to discuss how companies, entrepreneurs, and other buy-side stakeholders can partner with the NIH to bolster their pipeline. We can discuss partnership models beyond academic/basic research and SBIRs, success stories and